Surgery and BCG in Treating Patients With Bladder Cancer - Full Text View

Sponsored by:	European Organization for Research and Treatment of Cancer
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00002990

Purpose

RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing.

PURPOSE: This randomized phase III trial is studying four different regimens of BCG and comparing how well they work in treating patients who have undergone surgery for bladder cancer.

Condition	Intervention	Phase
Bladder Cancer	Biological: BCG vaccine	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Active Control
Official Title:	Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder

Resource links provided by NLM:

Genetics Home Reference related topics: bladder cancer

MedlinePlus related topics: Bladder Cancer Cancer Surgery

Drug Information available for: BCG Vaccine

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Dose equivalency with respect to duration of disease free interval, recurrence rate, percentage of patients with an increase in T-category to greater than T1, and the incidence of carcinoma in situ during follow-up [ Designated as safety issue: No ]
Dose equivalency in terms of fewer local and systemic side effects [ Designated as safety issue: Yes ]

Estimated Enrollment:	1288
Study Start Date:	March 1997

Detailed Description:

OBJECTIVES:

Demonstrate that after complete transurethral resection of all papillary tumors, one third dose BCG (Bacillus Calmette-Guerin vaccine; OncoTICE) is equivalent to full dose BCG and short term maintenance is equivalent to long term maintenance with respect to duration of disease free interval, recurrence rate, percentage of patients with an increase in T-category to greater than T1, and the incidence of carcinoma in situ during follow-up.
Demonstrate that one third dose BCG and short term maintenance are associated with fewer local and systemic side effects.

OUTLINE: This is a prospective randomized study.

At 7-15 days after transurethral resection, patients will begin receiving one of the following four regimens:

Regimen 1: One third dose Bacillus Calmette-Guerin (BCG) vaccine plus short term maintenance. Patients receive a one third dose of BCG instilled once a week for 6 weeks, followed by three weekly instillations at months 3, 6, and 12.
Regimen 2: Full dose BCG plus short term maintenance. Patients receive a full dose of BCG instilled once a week for 6 weeks, followed by three weekly instillations at months 3, 6, and 12.
Regimen 3: One third dose BCG plus long term maintenance. Patients receive a one third dose of BCG instilled once a week for 6 weeks, followed by three weekly instillations at months 3, 6, 12, 18, 24, 30 and 36.
Regimen 4: Full dose BCG plus long term maintenance. Patients receive a full dose of BCG instilled once a week for 6 weeks, followed by three weekly instillations at months 3, 6, 12, 18, 24, 30, and 36.

The patient is followed every 3 months for the first 3 years, and every 6 months thereafter.

PROJECTED ACCRUAL: 1288 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:	up to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed transitional cell carcinoma of the bladder of the following types:
- Multiple (not greater than 10), resectable, T1 or Ta, grade G1-G3
- Solitary T1 GIII tumor

PATIENT CHARACTERISTICS:

Age:

85 and under

Performance status:

WHO 0-2

Life expectancy:

Not specified

Hematopoietic:

WBC at least 3,000/mm^3
Platelet count at least 100,000/mm^3

Hepatic:

Values used to evaluate function may not exceed two times the upper limit of normal

Renal:

Values used to evaluate function may not exceed two times the upper limit of normal

Other:

No second malignancy except basal cell skin carcinoma
Not pregnant or nursing
No uncontrollable urinary tract infection
No active tuberculosis
No HIV antibody
No leukemia
No Hodgkin's disease
No transplant recipients

PRIOR CONCURRENT THERAPY:

Biologic therapy:

No prior treatment with BCG

Chemotherapy:

No cytostatic agents within the past 3 months

Endocrine therapy:

Not specified

Radiotherapy:

Not specified

Surgery:

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002990

Show 40 Study Locations

Sponsors and Collaborators

European Organization for Research and Treatment of Cancer

Investigators

Investigator:

A. P.M. Van Der Meijden, MD, PhD

Jeroen Bosch Ziekenhuis

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CDR0000065529, EORTC-30962
Study First Received:	November 1, 1999
Last Updated:	February 6, 2009
ClinicalTrials.gov Identifier:	NCT00002990 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

stage 0 bladder cancer
stage I bladder cancer
transitional cell carcinoma of the bladder

Study placed in the following topic categories:

BCG Vaccine
Urinary Tract Neoplasm
Cystocele
Immunologic Factors
Urinary Bladder Diseases
Adjuvants, Immunologic
Urinary Bladder Neoplasms
Urogenital Neoplasms

Carcinoma, Transitional Cell
Urologic Neoplasms
Carcinoma
Urologic Diseases
Carcinoma, Papillary
Bladder Neoplasm
Transitional Cell Carcinoma

Additional relevant MeSH terms:

BCG Vaccine
Neoplasms
Neoplasms by Site
Immunologic Factors
Urologic Diseases
Physiological Effects of Drugs

Urinary Bladder Diseases
Adjuvants, Immunologic
Urinary Bladder Neoplasms
Urogenital Neoplasms
Urologic Neoplasms
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 01, 2009